Pharmaceutical Formulation Containing Gelling Agent
14/460,170 | U.S. Patent Application
Interested in this case?
Request a Demo Track this case, and find millions of cases like it, let us show you how.Date | # | Transaction |
---|---|---|
10/23/2019 | 1-2-US-144601702AP1 | Abandonment Office Actions Communications |
10/23/2019 | Email Notification | |
10/23/2019 | Mail Abandonment for Failure to Respond to Office Action | |
10/17/2019 | Aband. for Failure to Respond to O. A. | |
7/8/2019 | 1-4-US-1446017028P1 | Advisory Action (PTOL-303) Office Actions Communications |
7/8/2019 | 5-2-US-1446017028P1 | After Final Consideration Program Decision |
7/8/2019 | 7-4-US-1446017028P1 | List of References cited by applicant and considered by examiner Documents including citations |
7/8/2019 | 11-1-US-1446017028P1 | Amendment After Final or under 37CFR 1.312, initialed by the examiner. In-house documents including Examiner Notes/Search Results |
7/8/2019 | Email Notification | |
7/8/2019 | Mail Advisory Action (PTOL - 303) | |
7/2/2019 | After Final Consideration Program Additional Consideration and/or updated search | |
7/2/2019 | Advisory Action (PTOL-303) | |
6/28/2019 | Information Disclosure Statement considered | |
6/11/2019 | Date Forwarded to Examiner | |
6/3/2019 | 1-1-US-1446017027P1 | Fee Worksheet (SB06) In-house documents including Examiner Notes/Search Results |
6/3/2019 | 1-1-US-1446017026P1 | Response After Final Action Written Arguments, Opinions, Incoming amendments, Papers received from applicants |
6/3/2019 | 2-2-US-1446017026P1 | After Final Consideration Program Request |
6/3/2019 | 4-2-US-1446017026P1 | EFS Acknowledgment Receipt Office Actions Communications |
6/3/2019 | 6-12-US-1446017026P1 | Applicant Arguments/Remarks Made in an Amendment Written Arguments, Opinions, Incoming amendments, Papers received from applicants |
6/3/2019 | 18-4-US-1446017026P1 | Claims Application Documents |
6/3/2019 | Response after Final Action | |
6/3/2019 | PILOT- Request for After Final Consideration Program | |
4/25/2019 | 1-4-US-1446017025P1 | Information Disclosure Statement (IDS) Form (SB08) Information Disclosure |
4/25/2019 | 5-17-US-1446017025P1 | Non Patent Literature |
4/25/2019 | 22-2-US-1446017025P1 | Non Patent Literature |
4/25/2019 | 24-2-US-1446017025P1 | Fee Worksheet (SB06) In-house documents including Examiner Notes/Search Results |
4/25/2019 | 26-3-US-1446017025P1 | EFS Acknowledgment Receipt Office Actions Communications |
4/25/2019 | 29-4-US-1446017025P1 | Transmittal Letter |
4/25/2019 | Electronic Information Disclosure Statement | |
4/25/2019 | Information Disclosure Statement (IDS) Filed | |
4/5/2019 | 1-16-US-1446017023P1 | Event:Office Action |
4/5/2019 | Electronic Review | |
4/5/2019 | Email Notification | |
4/5/2019 | Event:Office Action | |
4/1/2019 | Event:Office Action | |
1/10/2019 | Date Forwarded to Examiner | |
12/13/2018 | 1-1-US-1446017021P1 | Amendment/Req. Reconsideration-After Non-Final Reject Written Arguments, Opinions, Incoming amendments, Papers received from applicants |
12/13/2018 | 2-2-US-1446017021P1 | EFS Acknowledgment Receipt Office Actions Communications |
12/13/2018 | 4-13-US-1446017021P1 | Applicant Arguments/Remarks Made in an Amendment Written Arguments, Opinions, Incoming amendments, Papers received from applicants |
12/13/2018 | 17-4-US-1446017021P1 | Claims Application Documents |